The potential of selective COX-2 inhibitors in inflammatory and other diseases
It has been known since the 1960s that prostaglandins play a key role in inflammation, fever and pain. In 1971, Sir John Vane discovered that the efficacy of nonsteroidal antiinflammatory drugs (NSAIDs) is derived by inhibiting a key enzyme in prostaglandin biosynthesis (1). This enzyme has subsequently been identified as cyclooxygenase (COX). Presently, there are two known COX isoforms with distinct physiological functions, COX-1 and COX-2. COX-1 is a constitutively expressed protein found in most tissues. In the gastric mucosa, COX-1 is involved in the production of cytoprotective prostacyclin. In platelets, COX-1 is required for the generation of thromboxane A(2), which promotes platelet aggregation leading to thrombus formation. In contrast to COX-1, COX-2 is strongly inducible by a variety of mitogens such as cytokines and growth factors, and plays a key role in the production of inflammatory prostaglandins. A William Harvey Research Conference on Defining the role of COX-2 inhibitors in inflammatory and other diseases in Porto, Portugal brought together 15 invited speakers to present their current findings on the clinical significance of COX-2 and strategies for selectively targeting this isoform. Information presented at the conference is summarized below. (c) 2001 Prous Science. All rights reserved.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 37(2001), 3 vom: 01. März, Seite 181-185 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ho, Lap [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM125484275 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM125484275 | ||
| 003 | DE-627 | ||
| 005 | 20231222205817.0 | ||
| 007 | tu | ||
| 008 | 231222s2001 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0418.xml |
| 035 | |a (DE-627)NLM125484275 | ||
| 035 | |a (NLM)12783090 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ho, Lap |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential of selective COX-2 inhibitors in inflammatory and other diseases |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a It has been known since the 1960s that prostaglandins play a key role in inflammation, fever and pain. In 1971, Sir John Vane discovered that the efficacy of nonsteroidal antiinflammatory drugs (NSAIDs) is derived by inhibiting a key enzyme in prostaglandin biosynthesis (1). This enzyme has subsequently been identified as cyclooxygenase (COX). Presently, there are two known COX isoforms with distinct physiological functions, COX-1 and COX-2. COX-1 is a constitutively expressed protein found in most tissues. In the gastric mucosa, COX-1 is involved in the production of cytoprotective prostacyclin. In platelets, COX-1 is required for the generation of thromboxane A(2), which promotes platelet aggregation leading to thrombus formation. In contrast to COX-1, COX-2 is strongly inducible by a variety of mitogens such as cytokines and growth factors, and plays a key role in the production of inflammatory prostaglandins. A William Harvey Research Conference on Defining the role of COX-2 inhibitors in inflammatory and other diseases in Porto, Portugal brought together 15 invited speakers to present their current findings on the clinical significance of COX-2 and strategies for selectively targeting this isoform. Information presented at the conference is summarized below. (c) 2001 Prous Science. All rights reserved | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Pasinetti, Giulio Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 37(2001), 3 vom: 01. März, Seite 181-185 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2001 |g number:3 |g day:01 |g month:03 |g pages:181-185 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2001 |e 3 |b 01 |c 03 |h 181-185 | ||